-
Binge eating disorder among obese/overweight in Pakistan: Under-diagnosed, undertreated and misunderstood
Madeeha Malik, Waseem Shaukat and Azhar Hussain
Research Article: Clinical Investigation
-
Binge eating disorder among obese/overweight in Pakistan: Under-diagnosed, undertreated and misunderstood
Madeeha Malik, Waseem Shaukat and Azhar Hussain
Research Article: Clinical Investigation
-
Binge eating disorder among obese/overweight in Pakistan: Under-diagnosed, undertreated and misunderstood
Madeeha Malik, Waseem Shaukat and Azhar Hussain
Research Article: Clinical Investigation
-
Binge eating disorder among obese/overweight in Pakistan: Under-diagnosed, undertreated and misunderstood
Madeeha Malik, Waseem Shaukat and Azhar Hussain
Research Article: Clinical Investigation
-
Binge eating disorder among obese/overweight in Pakistan: Under-diagnosed, undertreated and misunderstood
Madeeha Malik, Waseem Shaukat and Azhar Hussain
Research Article: Clinical Investigation
-
Binge eating disorder among obese/overweight in Pakistan: Under-diagnosed, undertreated and misunderstood
Madeeha Malik, Waseem Shaukat and Azhar Hussain
Research Article: Clinical Investigation
-
Bevacizumab in the treatment of epithelial ovarian carcinoma
Brittany A Davidson & Angeles Alvarez Secord
Review: Clinical Trail Outcomes: Clinical Investigation
-
Bevacizumab in the treatment of epithelial ovarian carcinoma
Brittany A Davidson & Angeles Alvarez Secord
Review: Clinical Trail Outcomes: Clinical Investigation
-
Bevacizumab in the treatment of epithelial ovarian carcinoma
Brittany A Davidson & Angeles Alvarez Secord
Review: Clinical Trail Outcomes: Clinical Investigation
-
Bevacizumab in the treatment of epithelial ovarian carcinoma
Brittany A Davidson & Angeles Alvarez Secord
Review: Clinical Trail Outcomes: Clinical Investigation
-
Bevacizumab in the treatment of epithelial ovarian carcinoma
Brittany A Davidson & Angeles Alvarez Secord
Review: Clinical Trail Outcomes: Clinical Investigation
-
Bevacizumab in the treatment of epithelial ovarian carcinoma
Brittany A Davidson & Angeles Alvarez Secord
Review: Clinical Trail Outcomes: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Incentives and barriers to neurological clinical research participation
Anne S Lindblad, Pam Zingeser, Nil Sismanyazici-Navaie
Research Article: Clinical Investigation
-
Incentives and barriers to neurological clinical research participation
Anne S Lindblad, Pam Zingeser, Nil Sismanyazici-Navaie
Research Article: Clinical Investigation
-
Incentives and barriers to neurological clinical research participation
Anne S Lindblad, Pam Zingeser, Nil Sismanyazici-Navaie
Research Article: Clinical Investigation
-
Incentives and barriers to neurological clinical research participation
Anne S Lindblad, Pam Zingeser, Nil Sismanyazici-Navaie
Research Article: Clinical Investigation
-
Incentives and barriers to neurological clinical research participation
Anne S Lindblad, Pam Zingeser, Nil Sismanyazici-Navaie
Research Article: Clinical Investigation
-
Incentives and barriers to neurological clinical research participation
Anne S Lindblad, Pam Zingeser, Nil Sismanyazici-Navaie
Research Article: Clinical Investigation